1,371,638 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Purchased by Nantahala Capital Management LLC

Nantahala Capital Management LLC purchased a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,371,638 shares of the company's stock, valued at approximately $14,608,000. UroGen Pharma makes up about 0.6% of Nantahala Capital Management LLC's holdings, making the stock its 29th biggest holding. Nantahala Capital Management LLC owned approximately 5.85% of UroGen Pharma at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in UroGen Pharma during the fourth quarter worth approximately $59,000. Aquatic Capital Management LLC acquired a new stake in shares of UroGen Pharma during the fourth quarter worth $101,000. Oppenheimer & Co. Inc. purchased a new stake in shares of UroGen Pharma in the fourth quarter valued at $126,000. Susquehanna Fundamental Investments LLC acquired a new position in UroGen Pharma in the fourth quarter valued at $208,000. Finally, Legal & General Group Plc lifted its position in UroGen Pharma by 24.6% during the fourth quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock worth $211,000 after buying an additional 3,920 shares during the period. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

UroGen Pharma Stock Up 0.9 %

NASDAQ:URGN traded up $0.10 on Friday, reaching $11.51. The stock had a trading volume of 484,891 shares, compared to its average volume of 533,225. UroGen Pharma Ltd. has a 12-month low of $8.94 and a 12-month high of $20.70. The stock has a market cap of $530.54 million, a P/E ratio of -3.65 and a beta of 0.80. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The company has a 50-day moving average of $10.50 and a 200 day moving average of $11.07.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. On average, research analysts predict that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.

Analysts Set New Price Targets

URGN has been the subject of several recent analyst reports. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma in a report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target for the company. The Goldman Sachs Group cut their price target on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Scotiabank started coverage on UroGen Pharma in a research report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 target price on the stock. Guggenheim restated a "buy" rating on shares of UroGen Pharma in a research note on Tuesday. Finally, HC Wainwright reiterated a "buy" rating and set a $55.00 target price on shares of UroGen Pharma in a report on Monday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, UroGen Pharma currently has a consensus rating of "Buy" and an average target price of $32.86.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.